Stoke Therapeutics, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Stoke Therapeutics completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen for Dravet syndrome (June 2026), with data readout expected Q3 2027. The company holds $420M in cash ($354.3M as of June 30, 2026 plus $65.7M from subsequent ATM offering), expected to fund operations through potential U.S. commercialization in early 2028. R&D expenses surged to $49.5M in Q2 2026 vs. $25.9M in Q2 2025; net loss was $61.6M vs. $23.5M year-over-year. Pre-NDA meeting with FDA scheduled H2 2026; rolling NDA submission planned Q1 2027.
Why this rating
Phase 3 enrollment completion is pivotal milestone for lead program worth $420M/71% of market cap. Strong cash position de-risks near-term operations. Regulatory pathway clarity (pre-NDA, rolling submission) reduces approval uncertainty. Offset by sharply elevated burn rate ($89.2M R&D YTD) and revenue cliff post-Biogen license ($15.6M YTD vs. $172.4M in 2025).
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.